China Biologic Products 10-Q 5 Nov 13 2013 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Sep. 30, 2013	Nov. 05, 2013
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-13	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'
Trading Symbol	'CBPO	'
Entity Common Stock, Shares Outstanding	'	25,573,407
Entity Registrant Name	'China Biologic Products, Inc.	'
Entity Central Index Key	'0001369868	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Accelerated Filer	'

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2013	Dec. 31, 2012
Current Assets	'	'
Cash and cash equivalents	$131,496,674	$129,609,317
Accounts receivable, net of allowance for doubtful accounts	22,404,534	11,206,244
Inventories	83,676,773	75,679,173
Prepayments and other current assets	6,480,946	5,664,919
Total Current Assets	244,058,927	222,159,653
Property, plant and equipment, net	67,126,063	51,325,177
Intangible assets, net	2,840,550	3,541,582
Land use rights, net	7,038,767	5,818,709
Deposits related to land use rights	16,772,063	14,752,574
Restricted cash and deposit	32,064,962	2,912,145
Equity method investment	11,652,366	10,537,310
Total Assets	381,553,698	311,047,150
Current Liabilities	'	'
Short-term bank loans	4,890,000	7,935,000
Accounts payable	4,060,550	2,908,624
Due to related parties	4,208,582	4,081,624
Other payables and accrued expenses	29,625,322	25,423,349
Advance from customers	2,100,906	2,857,420
Income tax payable	5,483,734	4,513,075
Total Current Liabilities	50,369,094	47,719,092
Long-term bank loans	30,000,000	0
Deferred income	2,991,050	2,912,145
Other liabilities	3,468,575	2,996,749
Total Liabilities	86,828,719	53,627,986
Stockholders' Equity	'	'
Common stock: par value $0.0001; 100,000,000 shares authorized; 27,046,556 and 26,629,615 shares issued at September 30, 2013 and December 31, 2012, respectively; 25,566,852 and 26,629,615 shares outstanding at September 30, 2013 and December 31, 2012, respectively	2,704	2,663
Additional paid-in capital	68,698,856	62,251,731
Treasury stock, 1,479,704 and nil shares at September 30, 2013 and December 31, 2012, respectively, at cost	-29,594,080	0
Retained earnings	164,916,809	119,143,000
Accumulated other comprehensive income	20,477,319	14,072,322
Total equity attributable to China Biologic Products, Inc.	224,501,608	195,469,716
Noncontrolling interest	70,223,371	61,949,448
Total Stockholders' Equity	294,724,979	257,419,164
Commitments and contingencies	0	0
Total Liabilities and Stockholders' Equity	$381,553,698	$311,047,150

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Common Stock, Par Value Per Share	$0.00	$0.00
Common Stock, Shares Authorized	100,000,000	100,000,000
Common Stock, Shares, Issued	27,046,556	26,629,615
Common Stock, Shares, Outstanding	25,566,852	26,629,615
Treasury Stock, Shares	1,479,704	0

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Sales	$53,152,141	$53,124,050	$160,764,396	$150,817,850
Cost of sales	17,165,897	16,921,284	49,904,917	48,767,900
Gross profit	35,986,244	36,202,766	110,859,479	102,049,950
Operating expenses	'	'	'	'
Selling expenses	2,551,245	3,545,378	6,829,365	12,536,727
General and administrative expenses	9,218,798	11,599,779	26,771,966	26,677,945
Research and development expenses	1,053,383	637,397	2,801,625	2,277,474
Income from operations	23,162,818	20,420,212	74,456,523	60,557,804
Other income/ (expenses)	'	'	'	'
Equity in income of an equity method investee	642,579	744,976	1,382,524	2,219,279
Change in fair value of derivative liabilities	0	0	0	1,769,140
Interest expense	-306,656	-223,992	-741,569	-990,190
Interest income	1,320,263	561,761	2,964,082	1,870,873
Other income, net	0	449,815	0	347,029
Total other income, net	1,656,186	1,532,560	3,605,037	5,216,131
Earnings before income tax expense	24,819,004	21,952,772	78,061,560	65,773,935
Income tax expense	4,871,041	3,479,683	13,223,592	9,990,014
Net income	19,947,963	18,473,089	64,837,968	55,783,921
Less: Net income attributable to noncontrolling interest	5,251,940	4,855,939	19,064,159	16,370,694
Net income attributable to China Biologic Products, Inc.	14,696,023	13,617,150	45,773,809	39,413,227
Net income per share of common stock:	'	'	'	'
Basic	$0.55	$0.51	$1.71	$1.51
Diluted	$0.53	$0.50	$1.64	$1.41
Weighted average shares used in computation:	'	'	'	'
Basic	26,288,154	26,546,929	26,649,563	26,009,707
Diluted	27,449,081	27,018,904	27,780,005	26,741,713
Net income	19,947,963	18,473,089	64,837,968	55,783,921
Other comprehensive income:	'	'	'	'
Foreign currency translation adjustment, net of nil income taxes	1,985,434	-86,731	7,810,690	1,226,404
Comprehensive income	21,933,397	18,386,358	72,648,658	57,010,325
Less: Comprehensive income attributable to noncontrolling interest	5,586,905	4,926,035	20,469,852	16,692,803
Comprehensive income attributable to China Biologic Products, Inc.	$16,346,492	$13,460,323	$52,178,806	$40,317,522

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Treasury Stock [Member]	Accumulated other comprehensive income [Member]	Equity Attributable To China Biologic Products, Inc. [Member]	Noncontrolling Interest [Member]
Balance at Dec. 31, 2012	$257,419,164	$2,663	$62,251,731	$119,143,000	$0	$14,072,322	$195,469,716	$61,949,448
Balance (in shares) at Dec. 31, 2012	'	26,629,615	'	'	'	'	'	'
Net income	64,837,968	0	0	45,773,809	0	0	45,773,809	19,064,159
Other comprehensive income	7,810,690	0	0	0	0	6,404,997	6,404,997	1,405,693
Dividend declared by subsidiaries to noncontrolling interest	-10,896,678	0	0	0	0	0	0	-10,896,678
Acquisition of noncontrolling interests	-1,963,913	0	-664,662	0	0	0	-664,662	-1,299,251
Share repurchase	-29,594,080	0	0	0	-29,594,080	0	-29,594,080	0
Share repurchase (in shares)	'	0	'	'	'	'	'	'
Share-based compensation	4,076,817	0	4,076,817	0	0	0	4,076,817	0
Exercise of stock options	3,035,011	35	3,034,976	0	0	0	3,035,011	0
Exercise of stock options (in shares)	'	353,191	'	'	'	'	'	'
Vesting of restricted shares	0	6	-6	0	0	0	0	0
Vesting of restricted shares (in shares)	'	63,750	'	'	'	'	'	'
Balance at Sep. 30, 2013	$294,724,979	$2,704	$68,698,856	$164,916,809	($29,594,080)	$20,477,319	$224,501,608	$70,223,371
Balance (in shares) at Sep. 30, 2013	'	27,046,556	'	'	'	'	'	'

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'
Net income	$64,837,968	$55,783,921
Adjustments to reconcile net income to net cash provided by operating activities:	'	'
Depreciation	4,550,598	4,326,425
Amortization	1,027,650	2,293,839
(Gain)/ loss on sale of property, plant and equipment	-138,450	371,544
Allowance for doubtful accounts, net	0	21,876
Provision for doubtful accounts - other receivables and prepayments	37,453	94,567
Deferred tax expense/ (benefit)	428,037	-515,960
Share-based compensation	4,076,817	3,074,132
Change in fair value of derivative liabilities	0	-1,769,140
Equity in income of an equity method investee	-1,382,524	-2,219,279
Change in operating assets and liabilities:	'	'
Accounts receivable	-10,758,305	1,872,418
Prepayment and other current assets	-720,340	-468,800
Inventories	-5,872,632	3,507,968
Accounts payable	1,254,404	-1,103,617
Other payables and accrued expenses	1,088,481	-398,905
Advance from customers	-823,499	-939,904
Due to related parties	16,539	337,536
Income tax payable	837,760	517,440
Net cash provided by operating activities	58,459,957	64,786,061
CASH FLOWS FROM INVESTING ACTIVITIES:	'	'
Payment for property, plant and equipment	-17,076,459	-7,436,719
Payment for intangible assets and land use rights	-1,141,197	-796,707
Dividend received	560,980	1,109,115
Purchase of short-term investment	0	-2,731,300
Proceeds from sale of property, plant and equipment	175,808	0
Payment related to land use right	0	-13,220,568
Net cash used in investing activities	-17,480,868	-23,076,179
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'
Proceeds from stock option exercised	3,035,011	120,000
Proceeds from warrants exercised	0	4,500,000
Proceeds from short term bank loans	4,808,400	11,076,100
Repayment of short term bank loans	-8,014,000	-11,106,200
Proceeds from long term bank loans	30,000,000	0
Payment for deposit as security for long-term bank loans	-30,000,000	0
Payment for share repurchase	-29,594,080	0
Acquisition of noncontrolling interest	-1,963,913	0
Dividend paid by subsidiaries to noncontrolling interest shareholders	-10,896,678	-4,379,016
Net cash (used in) /provided by financing activities	-42,625,260	210,884
EFFECTS OF FOREIGN EXCHANGE RATE CHANGE ON CASH	3,533,528	390,585
NET INCREASE IN CASH AND CASH EQUIVALENTS	1,887,357	42,311,351
Cash and cash equivalents at beginning of period	129,609,317	89,411,835
Cash and cash equivalents at end of period	131,496,674	131,723,186
Supplemental cash flow information	'	'
Cash paid for income taxes	11,957,795	9,988,536
Cash paid for interest expense	273,095	296,901
Noncash investing and financing activities:	'	'
Acquisition of property, plant and equipment included in payables	1,502,623	0
Exercise of warrants that were liability classified	$0	$3,641,279

BASIS_OF_PRESENTATION_SIGNIFIC

BASIS OF PRESENTATION, SIGNIFICANT CONCENTRATION AND RISKS	9 Months Ended
	Sep. 30, 2013
Basis Of Presentation Significant Concentration and Risks [Abstract]	'
BASIS OF PRESENTATION, SIGNIFICANT CONCENTRATION AND RISKS	'
	NOTE 1 – BASIS OF PRESENTATION, SIGNIFICANT CONCENTRATION AND RISKS
	(a)	Basis of Presentation
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted as permitted by rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). The December 31, 2012 consolidated balance sheet was derived from the audited consolidated financial statements of China Biologic Products, Inc. (the “Company”). The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the December 31, 2012 audited consolidated financial statements of the Company included in the Company’s annual report on Form 10-K for the year ended December 31, 2012.
	In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present a fair statement of the financial position as of September 30, 2013, the results of operations for the three and nine months ended September 30, 2013 and 2012, and cash flows for the nine months ended September 30, 2013 and 2012, have been made. All significant intercompany transactions and balances are eliminated on consolidation.
	The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include the useful lives of property, plant and equipment and intangibles with definite lives, the allowance for doubtful accounts, the fair value determinations of equity instruments and stock compensation awards, the realizability of deferred tax assets and inventories, intangible assets, land use rights and property, plant and equipment, and accruals for income tax uncertainties and other contingencies.
	(b)	Significant Concentration and Risks
	The Company’s operations are carried out in the People’s Republic of China (the “PRC”) and are subject to specific considerations and significant risks not typically associated with companies in North America and Western Europe. Accordingly, the Company’s business, financial condition and results of operations may be influenced by the political, economic and legal environment in the PRC, and by the general state of the PRC economy. The Company’s results may be adversely affected by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other matters.
	The Company maintains cash and deposit balances at financial institutions which, from time to time, may exceed Federal Deposit Insurance Corporation insured limits for its bank accounts located in the United States or may exceed Hong Kong Deposit Protection Board insured limits for its bank accounts located in Hong Kong. Cash and deposit balances maintained at financial institutions or state-owned banks in the PRC are not covered by insurance. Total cash at banks and deposits as of September 30, 2013 and December 31, 2012 amounted to $162,673,942 and $132,201,606, respectively, of which $523,559 and $76,101 are insured, respectively. The Company has not experienced any losses in uninsured bank deposits and does not believe that it is exposed to any significant risks on cash held in bank accounts.
	The Company’s two major products are human albumin and human immunoglobulin for intravenous injection (“IVIG”). Human albumin accounted for 49.7% and 43.3% of the total sales for the three months ended September 30, 2013 and 2012, respectively, and 43.3% and 45.3% of the total sales for the nine months ended September 30, 2013 and 2012, respectively. IVIG accounted for 32.3% and 44.1% of the total sales for the three months ended September 30, 2013 and 2012, respectively, and 39.8% and 39.7% of the total sales for the nine months ended September 30, 2013 and 2012, respectively. If the market demands for human albumin and IVIG cannot be sustained in the future or the price of human albumin and IVIG decreases, the Company’s operating results could be adversely affected.
	Substantially all of the Company’s customers are located in the PRC.  There were no customers that individually comprised 10% or more of the total sales during the three and nine months ended September 30, 2013 and 2012, respectively. No individual customer represented 10% or more of trade receivables at September 30, 2013 and December 31, 2012, respectively. The Company performs ongoing credit evaluations of its customers’ financial condition and, generally, requires no collateral from its customers.
	There were no suppliers that comprised 10% or more of the total purchases for the three and nine months ended September 30, 2013 and 2012, respectively. One individual vendor represented more than 10% of accounts payable at September 30, 2013. Two vendors individually represented more than 10% of accounts payable at December 31, 2012.

ACCOUNTS_RECEIVABLE

ACCOUNTS RECEIVABLE	9 Months Ended
	Sep. 30, 2013
Receivables [Abstract]	'
ACCOUNTS RECEIVABLE	'
	NOTE 2 – ACCOUNTS RECEIVABLE
	Accounts receivable at September 30, 2013 and December 31, 2012 consisted of the following:
		September 30, 2013		December 31, 2012
		USD		USD
	Accounts receivable		22,831,402		11,621,851
	Less: Allowance for doubtful accounts		-426,868		-415,607
	Total		22,404,534		11,206,244
	No provision for doubtful accounts was recorded during the three months ended September 30, 2013 and 2012. A provision for doubtful accounts of nil and $21,876 was recorded for the nine months ended September 30, 2013 and 2012, respectively. There was no write-off of accounts receivable for the three and nine months ended September 30, 2013 and 2012, respectively.

INVENTORIES

INVENTORIES	9 Months Ended
	Sep. 30, 2013
Inventory Disclosure [Abstract]	'
INVENTORIES	'
	NOTE 3 – INVENTORIES
	Inventories at September 30, 2013 and December 31, 2012 consisted of the following:
		September 30, 2013		December 31, 2012
		USD		USD
	Raw materials		40,304,623		29,596,746
	Work-in-process		20,417,588		24,524,142
	Finished goods		22,954,562		21,558,285
	Total		83,676,773		75,679,173
	There were no write-down of inventories for the three and nine months ended September 30, 2013 and 2012.

PROPERTY_PLANT_AND_EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	9 Months Ended
	Sep. 30, 2013
Property, Plant and Equipment [Abstract]	'
PROPERTY, PLANT AND EQUIPMENT	'
	NOTE 4 – PROPERTY, PLANT AND EQUIPMENT
	Property, plant and equipment at September 30, 2013 and December 31, 2012 consisted of the following:
		September 30, 2013		December 31, 2012
		USD		USD
	Buildings		31,252,689		25,183,496
	Machinery and equipment		29,064,844		29,625,166
	Furniture, fixtures, office equipment and vehicles		7,210,615		6,513,482
	Total property, plant and equipment, gross		67,528,148		61,322,144
	Accumulated depreciation		-25,032,035		-24,356,752
	Total property, plant and equipment, net		42,496,113		36,965,392
	Construction in progress		21,021,486		3,501,404
	Prepayments for property, plant and equipment		3,608,464		10,858,381
	Property, plant and equipment, net		67,126,063		51,325,177
	Depreciation expense for the three months ended September 30, 2013 and 2012 was $1,444,859 and $2,045,202, respectively. Depreciation expense for the nine months ended September 30, 2013 and 2012 was $4,550,598 and $4,326,425, respectively.

INTANGIBLE_ASSETS_NET

INTANGIBLE ASSETS, NET	9 Months Ended
	Sep. 30, 2013
Finite-Lived Intangible Assets, Net [Abstract]	'
INTANGIBLE ASSETS, NET	'
	NOTE 5 – INTANGIBLE ASSETS, NET
	Intangible assets at September 30, 2013 and December 31, 2012 consisted of the following:
		September 30, 2013
		Weighted
		average	Gross		Net
		amortization	carrying	Accumulated	carrying
		period	amount	amortization	amount
			USD	USD	USD
	Amortizing intangible assets:
	Permits and licenses	10 years	5,122,788	-2,614,623	2,508,165
	GMP certificate	5 years	2,594,112	-2,445,289	148,823
	Long-term customer relationship	4 years	7,722,940	-7,722,940	-
	Others		344,343	-160,781	183,562
	Total		15,784,183	-12,943,633	2,840,550
		December 31, 2012
		Weighted
		average	Gross		Net
		amortization	carrying	Accumulated	carrying
		period	amount	amortization	amount
			USD	USD	USD
	Amortizing intangible assets:
	Permits and licenses	10 years	4,987,647	-2,119,622	2,868,025
	GMP certificate	5 years	2,525,679	-1,955,360	570,319
	Long-term customer relationship	4 years	7,519,206	-7,519,206	-
	Others		214,520	-111,282	103,238
	Total		15,247,052	-11,705,470	3,541,582
	Amortization expense for intangible assets was $257,318 and $730,994 for the three months ended September 30, 2013 and 2012, respectively. Amortization expense for intangible assets was $912,470 and $2,187,804 for the nine months ended September 30, 2013 and 2012, respectively. Estimated amortization expenses for the next five fiscal years are $513,226 in 2014, $511,439 in 2015, $505,852 in 2016, $471,598 in 2017 and $428,585 in 2018.

DEPOSITS_RELATED_TO_LAND_USE_R

DEPOSITS RELATED TO LAND USE RIGHTS	9 Months Ended
	Sep. 30, 2013
Deposits Related To Land Use Rights [Abstract]	'
DEPOSITS RELATED TO LAND USE RIGHTS	'
	NOTE 6 – DEPOSITS RELATED TO LAND USE RIGHTS
	At September 30, 2013, the deposits mainly represented a RMB83,400,000 (approximately $13,594,200) refundable payment made by Guizhou Taibang to the local government in connection with the public bidding for a land use right in Guizhou Province. The payment will be refunded within one year following the completion of the bidding process. If the Company is successful in the bid, the land use right will be used for the construction of a new manufacturing facility to comply with the new GMP standard effective by the end of 2013. However, due to potential delays in government approval procedures with respect to the land use right for such site, the Company may not be able to complete the construction of the new production facility as planned. In order to mitigate the operation disruption at Guizhou Taibang, the Company started to upgrade its existing production facility to meet the new GMP standard in June 2013. The production of the related facilities was suspended and the total production capacity of the Company is expected to decrease in part of 2013 and 2014.

RESTRICTED_CASH_AND_DEPOSIT

RESTRICTED CASH AND DEPOSIT	9 Months Ended
	Sep. 30, 2013
Restricted Cash and Investments [Abstract]	'
RESTRICTED CASH AND DEPOSIT	'
	NOTE 7 – RESTRICTED CASH  AND DEPOSIT
	On November 1, 2012, Guizhou Taibang entered into an agreement with the Financial Bureau of Huaxi District, Guiyang City. Pursuant to the agreement, the Financial Bureau of Huaxi District provided RMB18,350,000 (approximately $2,991,050) to Guizhou Taibang to subsidize the technical upgrade in respect of the new GMP standard (see Note 6). The agreement is valid for a three-year period. The usage of this fund is under the supervision of the Financial Bureau of Huaxi District and this fund cannot be used for other purposes. During the nine months ended September 30, 2013, RMB7,632,444 (approximately $1,244,088) was used in the technical upgrade in respect of the new GMP standard. At September 30, 2013, the balance of restricted cash was RMB10,717,556 (approximately $1,746,962).
	On August 7, 2013, the Company made a time deposit of RMB186,000,000 with China Merchants Bank Beijing Branch (“CMB BJ Branch”) as a security for an 18-month US$30,000,000 loan lent by China Merchants Bank Co., Ltd., New York Branch (“CMB NY Branch”) (see Note 8).

BANK_LOANS

BANK LOANS	9 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]	'
BANK LOANS	'
	NOTE 8 – BANK LOANS
	(a)	Short-term bank loans
	The Company’s short-term bank loans at September 30, 2013 and December 31, 2012 consisted of the following:
			Maturity	Annual
	Loans		date	interest rate		September 30, 2013	December 31, 2012
						USD	USD
	Short-term bank loan, unsecured		August 1, 2013	6	%	-	3,174,000
	Short-term bank loan, unsecured		September 3, 2013	6	%	-	3,174,000
	Short-term bank loan, unsecured		September 3, 2013	6	%	-	1,587,000
	Short-term bank loan, unsecured		May 12, 2014	6	%	4,890,000	-
	Total					4,890,000	7,935,000
	Interest expense on short-term bank loans was $79,195 and $91,919  for three months ended September 30, 2013 and 2012, respectively. Interest expense on short-term bank loans was $273,095 and $296,901 for the nine months ended September 30, 2013 and 2012, respectively.
	The Company did not have any revolving line of credit at September 30, 2013.
	(b)
	Long-term bank loans
	On August 8, 2013, the Company entered into a credit facility agreement with CMB NY Branch to finance the share repurchase (see Note 16). Pursuant to the facility agreement, CMB NY Branch lends to the Company an 18-month US$30,000,000 loan bearing an interest rate of 3-month LIBOR plus 1.6% per annum and a facility fee of 0.7% per annum. The loan is secured by a time deposit of RMB 186,000,000 (approximately $30,318,000) held at CMB BJ Branch.

INCOME_TAX

INCOME TAX	9 Months Ended
	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'
INCOME TAX	'
	NOTE 9 – INCOME TAX
	On October 31, 2011, Shandong Taibang received a notice from the Shandong provincial government that the High and New Technology Enterprise qualification has been renewed for an additional three years which entitled it to a 15% preferential income tax rate from 2011 to 2013.
	According to Cai Shui [2011] No. 58 dated July 27, 2011, Guizhou Taibang, being a qualified enterprise located in the western region of PRC, enjoys a preferential income tax rate of 15% effective retroactively from January 1, 2011 to December 31, 2020.
	The Company’s effective income tax rates were 20% and 16% for the three months ended September 30, 2013 and 2012, respectively. The Company’s effective income tax rates were 17% and 15% for the nine months ended September 30, 2013 and 2012, respectively.
	As of and for the nine months ended September 30, 2013, the Company did not have any unrecognized tax benefits and thus no interest and penalties related to unrecognized tax benefits were recorded. In addition, the Company does not expect that the amount of unrecognized tax benefits to change significantly within the next 12 months.

OPTIONS_AND_NONVESTED_SHARES

OPTIONS AND NONVESTED SHARES	9 Months Ended
	Sep. 30, 2013
Equity [Abstract]	'
OPTIONS AND NONVESTED SHARES	'
	NOTE 10 – OPTIONS AND NONVESTED SHARES
	Options
	A summary of stock options activity for the nine months ended September 30, 2013 is as follow:
		Number of Options		Weighted Average	Weighted Average	Aggregate Intrinsic
				Exercise Price	Remaining	Value
					Contractual Term
					in Years
				USD		USD
	Outstanding at December 31, 2012	2,648,609		9.39	7.65	18,374,422
	Granted	33,000		10.48
	Exercised	-353,191		8.59		4,669,588
	Forfeited and expired	-150,680		6.78
	Outstanding at September 30, 2013	2,177,738		9.71	7.2	42,462,885
	Vested and expected to vest	2,177,738		9.71	7.2	42,462,885
	Exercisable at September 30, 2013	1,617,738		9.73	6.66	31,509,285
	The 33,000 stock options granted during the nine months ended September 30, 2013 had a weighted average fair value of $8.37 per share or an aggregate of $276,250 on the date of grant, determined based on the Black-Scholes option pricing model using the following weighted average assumptions:
		For the nine months ended
		September 30, 2013
	Expected volatility		104	%
	Expected dividends yield		0	%
	Expected term		5 years
	Risk-free interest rate (per annum)		0.72	%
	Fair value of underlying ordinary shares (per share)	$	10.57
	For the three months ended September 30, 2013 and 2012, the Company recorded stock compensation expense of $651,047 and $1,028,860, respectively, in general and administrative expenses. For the nine months ended September 30, 2013 and 2012, the Company recorded stock compensation expense of $3,346,046 and $3,021,818, respectively, in general and administrative expenses.
	At September 30, 2013, approximately $4,082,914 of stock compensation expense with respect to the non-vested stock options is expected to be recognized over approximately 2.49 years.
	Nonvested shares
	A summary of nonvested shares activity for the nine months ended September 30, 2013 is as follows:
		Number of		Grant date weighted
		nonvested shares		average fair value
				USD
	Outstanding at December 31, 2012	120,000		9.85
	Granted	296,500		22.74
	Vested	-63,750		9.85
	Forfeited	-		-
	Outstanding at September 30, 2013	352,750		20.68
	For the three months ended September 30, 2013 and 2012, the Company recorded stock compensation expense of $377,808 and $52,314 respectively in general and administrative expenses. For the nine months ended September 30, 2013 and 2012, the Company recorded stock compensation expense of $730,771 and $52,314 respectively in general and administrative expenses.
	At September 30, 2013, approximately $6,983,867 of stock compensation expense with respect to nonvested shares is expected to be recognized over approximately 3.43 years.

FAIR_VALUE_MEASUREMENTS

FAIR VALUE MEASUREMENTS	9 Months Ended
	Sep. 30, 2013
Fair Value Disclosures [Abstract]	'
FAIR VALUE MEASUREMENTS	'
	NOTE 11 – FAIR VALUE MEASUREMENTS
	Management used the following methods and assumptions to estimate the fair value of financial instruments at the relevant balance sheet dates:
	•	Short-term financial instruments (including cash, accounts receivable, other receivables, short-term bank loans, accounts payable, other payables and accrued expenses, and amount due to related parties) – The carrying amounts of the short-term financial instruments approximate their fair values because of the short maturity of these instruments.
	•	Restricted deposit – The carrying amounts of the restricted deposit approximate their fair value. The fair value is estimated using discounted cash flow analysis based on the Company’s incremental borrowing rates for similar borrowing.
	•	Long-term bank loan – fair value is based on the amount of future cash flows associated with the long-term bank loan discounted at the Company’s current borrowing rate for similar debt instruments of comparable terms. The carrying value of the long-term bank loan approximate its fair value as the long-term bank loan carry variable interest rate which approximate rate currently offered by the Company’s bankers for similar debt instruments of comparable maturities.

SALES

SALES	9 Months Ended
	Sep. 30, 2013
Sales [Abstract]	'
SALES	'
	NOTE 12 – SALES
	The Company’s sales are primarily derived from the manufacture and sale of Human Albumin and Immunoglobulin products. The Company’s sales by significant types of product for the three months ended September 30, 2013 and 2012 are as follows:
		For the three months ended
		September 30,	September 30,
		2013	2012
		USD	USD
	Human Albumin	26,420,902	22,990,891
	Immunoglobulin products:
	Human Immunoglobulin for Intravenous Injection	17,162,545	23,412,548
	Other Immunoglobulin products	5,355,020	3,685,613
	Placenta Polypeptide	2,762,092	2,726,801
	Others	1,451,582	308,197
	Total	53,152,141	53,124,050
	The Company’s sales by significant types of product for the nine months ended September 30, 2013 and 2012 are as follows:
		For the nine months ended
		September 30,	September 30,
		2013	2012
		USD	USD
	Human Albumin	69,686,924	68,320,593
	Immunoglobulin products:
	Human Immunoglobulin for Intravenous Injection	63,921,570	59,913,448
	Other Immunoglobulin products	15,949,006	14,458,714
	Placenta Polypeptide	7,984,246	7,346,812
	Others	3,222,650	778,283
	Total	160,764,396	150,817,850

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'
COMMITMENTS AND CONTINGENCIES	'
	NOTE 13 – COMMITMENTS AND CONTINGENCIES
	Capital commitments
	At September 30, 2013, commitments outstanding for the purchase of property, plant and equipment approximated $4,800,000.
	Legal proceedings
	Dispute among Guizhou Taibang Shareholders over Raising Additional Capital
	In May 2007, a 91% majority of Guizhou Taibang’s shareholders approved a plan to raise additional capital from private strategic investors through the issuance of an additional 20,000,000 shares of Guizhou Taibang at RMB2.80 per share. The plan required all existing Guizhou Taibang shareholders to waive their rights of first refusal to subscribe for the additional shares. The remaining 9% minority shareholder of Guizhou Taibang’s shares, Guizhou Jie’an Company (“Jie’an”), did not support the plan and did not waive its right of first refusal. In May 2007, the majority shareholders caused Guizhou Taibang to sign an Equity Purchase Agreement with certain investors, pursuant to which the investors agreed to invest an aggregate of $7,475,832 (or RMB50,960,000) in exchange for 18,200,000 shares, or 21.4%, of Guizhou Taibang’s equity interests. At the same time, Jie’an also subscribed for 1,800,000 shares, representing its pro rata share of the 20,000,000 shares being offered. The proceeds from all parties were received by Guizhou Taibang in accordance with the agreement.
	In June 2007, Jie’an brought suit in the High Court of Guizhou province, China, against Guizhou Taibang and the three other original shareholders of Guizhou Taibang, alleging the illegality of the Equity Purchase Agreement. In its complaint, Jie’an claimed that it had a right to acquire the 18,200,000 shares offered to the strategic investors under the Equity Purchase Agreement. In September 2008, the Guizhou High Court ruled against Jie’an and sustained the Equity Purchase Agreement. In November 2008, Jie’an appealed the Guizhou High Court judgment to the People’s Supreme Court in Beijing. In May 2009, the People’s Supreme Court sustained the original ruling and denied the rights of first refusal of Jie’an over the 18,200,000 shares.
	During the second quarter of 2010, Jie’an requested that Guizhou Taibang register its 1.8 million shares of additional capital injection with the local Administration for Industry and Commerce, or AIC, pursuant to the Equity Purchase Agreement, and such request was approved by the majority shareholders of Guizhou Taibang in a shareholders meeting held in the second quarter of 2010. However, the Board of Directors of the Company is withholding its required ratification of the shareholders’ approval of Jie’an’s request, pending the outcome of the ongoing litigation. In March 2012, the Company received a subpoena that Jie’an brought suit in the People’s Court of Huaxi District, Guizhou Province, against Guizhou Taibang, alleging Guizhou Taibang’s withholding of its request. Jie’an requested that Guizhou Taibang register its 1.8 million shares of capital injection, pay dividends associated with these shares, as well as the related interest and penalty from May 2007 to December 2011 amounting to $3,967,500 (or RMB25,000,000) in aggregate, and return the over-paid subscription of $228,528 (or RMB1,440,000), as well as the interest and penalty, amounting to $1,587,000 (or RMB10,000,000) in aggregate. The People’s Court of Huaxi District, Guizhou Province, has accepted Jie’an’s suit. In May 2012, Guizhou Taibang was informed by the court that the case was postponed upon the request from Jie’an and no exact hearing date has been provided as of the date of this report. If the Company decides to ratify the approval or the case is ruled in Jie’an’s favor, Dalin’s ownership in Guizhou Taibang will be diluted from 54% to 52.54% and Jie’an may be entitled to receive its pro rata share of Guizhou Taibang’s profits since the date of Jie’an’s capital contribution became effective. As this case is closely tied to the outcome of the strategic investors’ dispute stated below, the Company does not expect Jie’an to prevail. At September 30, 2013, the Company had recorded, in its balance sheet, payables to Jie’an in the amounts of RMB5,040,000 (approximately $821,520) for the additional funds received in relation to the 1.8 million shares of capital infusion, RMB1,440,000 (approximately $234,720) for the over-paid subscription and RMB2,837,024 (approximately $462,435) for the accrued interest.
	As a result of this dispute, the strategic investors’ equity ownership in Guizhou Taibang and the related increase in registered capital of Guizhou Taibang have not been registered with the local AIC. In January 2010, the strategic investors brought suit in the High Court of Guizhou Province against Guizhou Taibang alleging Guizhou Taibang’s failure to register their equity interest in Guizhou Taibang with the local AIC and requesting the distribution of their share of Guizhou Taibang’s dividends declared since 2007. Dalin was also joined as a co-defendant as it is the majority shareholder and exercises control over Guizhou Taibang’s day-to-day operations.
	In October, 2010, the High Court of Guizhou ruled in favor of the Company and denied the strategic investors’ right as shareholders of Guizhou Taibang, as well as their entitlement to the dividends. In light of the Guizhou ruling, the Company returned the proceeds of $1,699,040 (or RMB11,200,000) to one of the strategic investors in November 2010. In October 2010, the other strategic investors appealed to the PRC Supreme Court in Beijing on the ruling of the High Court of Guizhou. The PRC Supreme Court overruled the decision of the High Court of Guizhou and remanded the case to the High Court of Guizhou for retrial. In January 2012, the strategic investors re-filed their case to the High Court of Guizhou requesting, in addition to the share distribution, the distribution of dividends and interest in the amount of RMB18,349,345 (approximately $2,990,943) and RMB2,847,000 (approximately $464,061), respectively. In December 2012, the High Court of Guizhou affirmed the judgment against the strategic investors. In January 2013, the strategic investors appealed to the PRC Supreme Court in Beijing on the ruling again. The PRC Supreme Court accepted the case for retrial.
	In April 2013, the Company countersued the strategic investors in the Intermediate Court of Guiyang City alleging their breach of the Security Law in the PRC and requested a consideration of $6,064,800 (or RMB38,000,000) for the related expenses and losses, and Guizhou Intermediate Court accepted the case. The Company is awaiting the hearing of the above case as of the date of this report.
	In September 2013, the PRC Supreme Court made the final judgement against the strategic investors and denied the strategic investors’ right as shareholders of Guizhou Taibang and their claim for the related dividend distribution. At September 30, 2013, Guizhou Taibang has made provision for the strategic investors’ initial fund along with RMB16,558,473 (approximately $2,699,031) in accrued interest, and RMB509,600 (approximately $83,065) for the 1% penalty imposed by the agreement for any breach in the event that Guizhou Taibang is required to return their original investment amount to the strategic investors.

RELATED_PARTY_TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2013
Related Party Transactions [Abstract]	'
RELATED PARTY TRANSACTIONS	'
	NOTE 14 – RELATED PARTY TRANSACTIONS
	The material related party transactions undertaken by the Company for the three months ended September 30, 2013 and 2012 are as follows:
			For the three months ended
				September 30, 2013		September 30, 2012
				USD		USD
	Commission expenses with related parties(1)			815,410		1,014,193
	The material related party transactions undertaken by the Company for the nine months ended September 30, 2013 and 2012 are as follows:
		For the nine months ended
		September 30, 2013		September 30, 2012
		USD		USD
	Commission expenses with related parties(1)	2,367,722			2,594,281
	The related party balances at September 30, 2013 and December 31, 2012 are presented as follows:
	Liabilities		Purpose		September 30, 2013	December 31, 2012
					USD	USD
	Other payable – a related party(1)		Commission		316,627	339,272
	Other payable – a related party(2)		Loan		2,373,280	2,311,044
	Other payable – a related party(3)		Contribution		1,518,675	1,431,308
	Total other payable – related parties				4,208,582	4,081,624
	(1)During the year ended December 31, 2011, Guizhou Taibang signed an agency contract with Guizhou Eakan Co., Ltd. (“Guizhou Eakan”), an affiliate of one of the Guizhou Taibang’s noncontrolling interest shareholders, pursuant to which Guizhou Taibang would pay commission to Guizhou Eakan for the promotion of the product of Placenta Polypeptide. At September 30, 2013, Guizhou Taibang accrued commission payable of $316,627 for service rendered by Guizhou Eakan. For the three months ended September 30, 2013, commission expense for service rendered by Guizhou Eakan was $815,410. For the nine months ended September 30, 2013, commission expense for service rendered by Guizhou Eakan was $2,367,722.
	(2)Guizhou Taibang has payables to Guizhou Eakan Investing Corp., amounting to approximately $2,373,280 and $2,311,044 at September 30, 2013 and December 31, 2012, respectively. Guizhou Eakan Investing Corp. is one of the noncontrolling interest shareholders of Guizhou Taibang. The Company borrowed this interest free advance for working capital purpose for Guizhou Taibang. The balance is due on demand.
	(3)Guizhou Taibang has payables to Jie’an, a noncontrolling interest shareholder of Guizhou Taibang, amounting to approximately $1,518,675 and $1,431,308 at September 30, 2013 and December 31, 2012, respectively. In 2007, Guizhou Taibang received additional contributions from Jie’an of $962,853 (or RMB6,480,000) to maintain Jie’an’s equity interest in Guizhou Taibang at 9%. However, due to a legal dispute among shareholders over raising additional capital as discussed in the legal proceeding section (see Note 13), the contribution is subject to be returned to Jie’an. During the second quarter of 2010, Jie’an requested that Guizhou Taibang register its 1.8 million shares of additional capital contribution with the local AIC, pursuant to the Equity Purchase Agreement, and such registration was approved by the majority shareholders of Guizhou Taibang in a shareholders’ meeting held in the second quarter of 2010. However, the Board of Directors of the Company is withholding its required ratification of the shareholders’ approval of Jie’an’s request until the completion of the ongoing litigations. If the Company decided to ratify the approval, Dalin’s ownership in Guizhou Taibang will be diluted from 54% to 52.54% and Jie’an will be entitled to receive its pro rata share of Guizhou Taibang’s profits since the date of Jie’an contribution became effective. As this case is closely tied to the outcome of the strategic investors’ dispute stated above, the Company has set aside Jie’an’s additional fund of RMB5,040,000 (approximately $821,520), the over-paid subscription of RMB1,440,000 (approximately $234,720) along with RMB2,837,024 (approximately $462,435) in accrued interest and penalty at September 30, 2013.

NET_INCOME_PER_SHARE

NET INCOME PER SHARE	9 Months Ended
	Sep. 30, 2013
Net Income Loss Per Share Disclosure [Abstract]	'
NET INCOME PER SHARE	'
	NOTE 15 - NET INCOME PER SHARE
	The following table sets forth the computation of basic and diluted net income per share for the periods indicated:
		For the three months ended
		September 30, 2013	September 30, 2012
		USD	USD
	Net income attributable to China Biologic Products, Inc.	14,696,023	13,617,150
	Earnings allocated to participating nonvested shares	-143,220	-20,709
	Net income used in basic/diluted net income per common stock	14,552,803	13,596,441
	Weighted average shares used in computing basic net income per common	26,288,154	26,546,929
	stock
	Diluted effect of stock option	1,160,927	471,975
	Weighted average shares used in computing diluted net income per common	27,449,081	27,018,904
	stock
	Net income per common stock – basic	0.55	0.51
	Net income per common stock – diluted	0.53	0.5
	During the three months ended September 30, 2013, no option was antidilutive and excluded from the calculation of diluted net income per common stock.
	During the three months ended September 30, 2012, 1,979,333 options with an average exercise price of $11.37 were excluded from the calculation of diluted net income per common stock since they were antidilutive.
	The following table sets forth the computation of basic and diluted net income per share for the periods indicated:
		For the nine months ended
		September 30, 2013	September 30, 2012
		USD	USD
	Net income attributable to China Biologic Products, Inc.	45,773,809	39,413,227
	Earnings allocated to participating nonvested shares	-303,490	-20,562
	Net income allocated to common stockholders used in computing basic net	45,470,319	39,392,665
	income per common stock
	Change in fair value of warrants	-	-1,769,140
	Net income used in diluted net income per common stock	45,470,319	37,623,525
	Weighted average shares used in computing basic net income per common	26,649,563	26,009,707
	stock
	Diluted effect of warrants	-	266,999
	Diluted effect of stock option	1,130,442	465,007
	Weighted average shares used in computing diluted net income per common	27,780,005	26,741,713
	stock
	Net income per common stock – basic	1.71	1.51
	Net income per common stock – diluted	1.64	1.41
	During the nine months ended September 30, 2013, no option was antidilutive and excluded from the calculation of diluted net income per common stock.
	During the nine months ended September 30, 2012, 1,979,333 options with an average exercise price of $11.37 were excluded from the calculation of diluted net income per common stock since they were antidilutive.

SHARE_REPURCHASE

SHARE REPURCHASE	9 Months Ended
	Sep. 30, 2013
Other Liabilities Disclosure [Abstract]	'
SHARE REPURCHASE	'
	NOTE 16 – SHARE REPURCHASE
	On August 2, 2013, the Company entered into an agreement with one of its individual shareholders, pursuant to which the Company repurchased 1,479,704 shares of common stock for a consideration of US$29,594,080. The transaction was completed on August 8, 2013.

BASIS_OF_PRESENTATION_SIGNIFIC1

BASIS OF PRESENTATION, SIGNIFICANT CONCENTRATION AND RISKS (Policies)	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Basis of Presentation	'
	(a)	Basis of Presentation
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted as permitted by rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). The December 31, 2012 consolidated balance sheet was derived from the audited consolidated financial statements of China Biologic Products, Inc. (the “Company”). The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the December 31, 2012 audited consolidated financial statements of the Company included in the Company’s annual report on Form 10-K for the year ended December 31, 2012.
	In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present a fair statement of the financial position as of September 30, 2013, the results of operations for the three and nine months ended September 30, 2013 and 2012, and cash flows for the nine months ended September 30, 2013 and 2012, have been made. All significant intercompany transactions and balances are eliminated on consolidation.
	The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include the useful lives of property, plant and equipment and intangibles with definite lives, the allowance for doubtful accounts, the fair value determinations of equity instruments and stock compensation awards, the realizability of deferred tax assets and inventories, intangible assets, land use rights and property, plant and equipment, and accruals for income tax uncertainties and other contingencies.
Significant Concentration and Risks	'
	(b)	Significant Concentration and Risks
	The Company’s operations are carried out in the People’s Republic of China (the “PRC”) and are subject to specific considerations and significant risks not typically associated with companies in North America and Western Europe. Accordingly, the Company’s business, financial condition and results of operations may be influenced by the political, economic and legal environment in the PRC, and by the general state of the PRC economy. The Company’s results may be adversely affected by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other matters.
	The Company maintains cash and deposit balances at financial institutions which, from time to time, may exceed Federal Deposit Insurance Corporation insured limits for its bank accounts located in the United States or may exceed Hong Kong Deposit Protection Board insured limits for its bank accounts located in Hong Kong. Cash and deposit balances maintained at financial institutions or state-owned banks in the PRC are not covered by insurance. Total cash at banks and deposits as of September 30, 2013 and December 31, 2012 amounted to $162,673,942 and $132,201,606, respectively, of which $523,559 and $76,101 are insured, respectively. The Company has not experienced any losses in uninsured bank deposits and does not believe that it is exposed to any significant risks on cash held in bank accounts.
	The Company’s two major products are human albumin and human immunoglobulin for intravenous injection (“IVIG”). Human albumin accounted for 49.7% and 43.3% of the total sales for the three months ended September 30, 2013 and 2012, respectively, and 43.3% and 45.3% of the total sales for the nine months ended September 30, 2013 and 2012, respectively. IVIG accounted for 32.3% and 44.1% of the total sales for the three months ended September 30, 2013 and 2012, respectively, and 39.8% and 39.7% of the total sales for the nine months ended September 30, 2013 and 2012, respectively. If the market demands for human albumin and IVIG cannot be sustained in the future or the price of human albumin and IVIG decreases, the Company’s operating results could be adversely affected.
	Substantially all of the Company’s customers are located in the PRC.  There were no customers that individually comprised 10% or more of the total sales during the three and nine months ended September 30, 2013 and 2012, respectively. No individual customer represented 10% or more of trade receivables at September 30, 2013 and December 31, 2012, respectively. The Company performs ongoing credit evaluations of its customers’ financial condition and, generally, requires no collateral from its customers.
	There were no suppliers that comprised 10% or more of the total purchases for the three and nine months ended September 30, 2013 and 2012, respectively. One individual vendor represented more than 10% of accounts payable at September 30, 2013. Two vendors individually represented more than 10% of accounts payable at December 31, 2012.

ACCOUNTS_RECEIVABLE_Tables

ACCOUNTS RECEIVABLE (Tables)	9 Months Ended
	Sep. 30, 2013
Receivables [Abstract]	'
SCHEDULE OF ACCOUNTS RECEIVABLE	'
	Accounts receivable at September 30, 2013 and December 31, 2012 consisted of the following:
		September 30, 2013		December 31, 2012
		USD		USD
	Accounts receivable		22,831,402		11,621,851
	Less: Allowance for doubtful accounts		-426,868		-415,607
	Total		22,404,534		11,206,244

INVENTORIES_Tables

INVENTORIES (Tables)	9 Months Ended
	Sep. 30, 2013
Inventory Disclosure [Abstract]	'
SCHEDULE OF INVENTORIES	'
	Inventories at September 30, 2013 and December 31, 2012 consisted of the following:
		September 30, 2013		December 31, 2012
		USD		USD
	Raw materials		40,304,623		29,596,746
	Work-in-process		20,417,588		24,524,142
	Finished goods		22,954,562		21,558,285
	Total		83,676,773		75,679,173

PROPERTY_PLANT_AND_EQUIPMENT_T

PROPERTY, PLANT AND EQUIPMENT (Tables)	9 Months Ended
	Sep. 30, 2013
Property, Plant and Equipment [Abstract]	'
SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT	'
	Property, plant and equipment at September 30, 2013 and December 31, 2012 consisted of the following:
		September 30, 2013		December 31, 2012
		USD		USD
	Buildings		31,252,689		25,183,496
	Machinery and equipment		29,064,844		29,625,166
	Furniture, fixtures, office equipment and vehicles		7,210,615		6,513,482
	Total property, plant and equipment, gross		67,528,148		61,322,144
	Accumulated depreciation		-25,032,035		-24,356,752
	Total property, plant and equipment, net		42,496,113		36,965,392
	Construction in progress		21,021,486		3,501,404
	Prepayments for property, plant and equipment		3,608,464		10,858,381
	Property, plant and equipment, net		67,126,063		51,325,177

INTANGIBLE_ASSETS_NET_Tables

INTANGIBLE ASSETS, NET (Tables)	9 Months Ended
	Sep. 30, 2013
Intangible Assets Disclosure [Abstract]	'
SCHEDULE OF INTANGIBLE ASSETS	'
	Intangible assets at September 30, 2013 and December 31, 2012 consisted of the following:
		September 30, 2013
		Weighted
		average	Gross		Net
		amortization	carrying	Accumulated	carrying
		period	amount	amortization	amount
			USD	USD	USD
	Amortizing intangible assets:
	Permits and licenses	10 years	5,122,788	-2,614,623	2,508,165
	GMP certificate	5 years	2,594,112	-2,445,289	148,823
	Long-term customer relationship	4 years	7,722,940	-7,722,940	-
	Others		344,343	-160,781	183,562
	Total		15,784,183	-12,943,633	2,840,550
		December 31, 2012
		Weighted
		average	Gross		Net
		amortization	carrying	Accumulated	carrying
		period	amount	amortization	amount
			USD	USD	USD
	Amortizing intangible assets:
	Permits and licenses	10 years	4,987,647	-2,119,622	2,868,025
	GMP certificate	5 years	2,525,679	-1,955,360	570,319
	Long-term customer relationship	4 years	7,519,206	-7,519,206	-
	Others		214,520	-111,282	103,238
	Total		15,247,052	-11,705,470	3,541,582

BANK_LOANS_Tables

BANK LOANS (Tables)	9 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]	'
SCHEDULE OF SHORT-TERM BANK LOANS	'
	The Company’s short-term bank loans at September 30, 2013 and December 31, 2012 consisted of the following:
		Maturity	Annual
	Loans	date	interest rate		September 30, 2013	December 31, 2012
					USD	USD
	Short-term bank loan, unsecured	August 1, 2013	6	%	-	3,174,000
	Short-term bank loan, unsecured	September 3, 2013	6	%	-	3,174,000
	Short-term bank loan, unsecured	September 3, 2013	6	%	-	1,587,000
	Short-term bank loan, unsecured	May 12, 2014	6	%	4,890,000	-
	Total				4,890,000	7,935,000

OPTIONS_AND_NONVESTED_SHARES_T

OPTIONS AND NONVESTED SHARES (Tables)	9 Months Ended
	Sep. 30, 2013
Options and Nonvested Shares [Abstract]	'
SCHEDULE OF STOCK OPTIONS ACTIVITY	'
	A summary of stock options activity for the nine months ended September 30, 2013 is as follow:
		Number of Options		Weighted Average	Weighted Average	Aggregate Intrinsic
				Exercise Price	Remaining	Value
					Contractual Term
					in Years
				USD		USD
	Outstanding at December 31, 2012	2,648,609		9.39	7.65	18,374,422
	Granted	33,000		10.48
	Exercised	-353,191		8.59		4,669,588
	Forfeited and expired	-150,680		6.78
	Outstanding at September 30, 2013	2,177,738		9.71	7.2	42,462,885
	Vested and expected to vest	2,177,738		9.71	7.2	42,462,885
	Exercisable at September 30, 2013	1,617,738		9.73	6.66	31,509,285
SCHEDULE OF STOCK OPTIONS VALUATION ASSUMPTION	'
		For the nine months ended
		September 30, 2013
	Expected volatility		104	%
	Expected dividends yield		0	%
	Expected term		5 years
	Risk-free interest rate (per annum)		0.72	%
	Fair value of underlying ordinary shares (per share)	$	10.57
SCHEDULE OF NONVESTED SHARES ACTIVITY	'
	A summary of nonvested shares activity for the nine months ended September 30, 2013 is as follows:
		Number of		Grant date weighted
		nonvested shares		average fair value
				USD
	Outstanding at December 31, 2012	120,000		9.85
	Granted	296,500		22.74
	Vested	-63,750		9.85
	Forfeited	-		-
	Outstanding at September 30, 2013	352,750		20.68

SALES_Tables

SALES (Tables)	9 Months Ended
	Sep. 30, 2013
Sales Disclosure [Abstract]	'
SCHEDULE OF SALES BY PRODUCT TYPE	'
	The Company’s sales are primarily derived from the manufacture and sale of Human Albumin and Immunoglobulin products. The Company’s sales by significant types of product for the three months ended September 30, 2013 and 2012 are as follows:
		For the three months ended
		September 30,	September 30,
		2013	2012
		USD	USD
	Human Albumin	26,420,902	22,990,891
	Immunoglobulin products:
	Human Immunoglobulin for Intravenous Injection	17,162,545	23,412,548
	Other Immunoglobulin products	5,355,020	3,685,613
	Placenta Polypeptide	2,762,092	2,726,801
	Others	1,451,582	308,197
	Total	53,152,141	53,124,050
	The Company’s sales by significant types of product for the nine months ended September 30, 2013 and 2012 are as follows:
		For the nine months ended
		September 30,	September 30,
		2013	2012
		USD	USD
	Human Albumin	69,686,924	68,320,593
	Immunoglobulin products:
	Human Immunoglobulin for Intravenous Injection	63,921,570	59,913,448
	Other Immunoglobulin products	15,949,006	14,458,714
	Placenta Polypeptide	7,984,246	7,346,812
	Others	3,222,650	778,283
	Total	160,764,396	150,817,850

RELATED_PARTY_TRANSACTIONS_Tab

RELATED PARTY TRANSACTIONS (Tables)	9 Months Ended
	Sep. 30, 2013
Related Party Transactions [Abstract]	'
SCHEDULE OF RELATED PARTY TRANSACTION	'
	The material related party transactions undertaken by the Company for the three months ended September 30, 2013 and 2012 are as follows:
			For the three months ended
				September 30, 2013		September 30, 2012
				USD		USD
	Commission expenses with related parties(1)			815,410		1,014,193
	The material related party transactions undertaken by the Company for the nine months ended September 30, 2013 and 2012 are as follows:
		For the nine months ended
		September 30, 2013		September 30, 2012
		USD		USD
	Commission expenses with related parties(1)	2,367,722			2,594,281
	(1)During the year ended December 31, 2011, Guizhou Taibang signed an agency contract with Guizhou Eakan Co., Ltd. (“Guizhou Eakan”), an affiliate of one of the Guizhou Taibang’s noncontrolling interest shareholders, pursuant to which Guizhou Taibang would pay commission to Guizhou Eakan for the promotion of the product of Placenta Polypeptide. At September 30, 2013, Guizhou Taibang accrued commission payable of $316,627 for service rendered by Guizhou Eakan. For the three months ended September 30, 2013, commission expense for service rendered by Guizhou Eakan was $815,410. For the nine months ended September 30, 2013, commission expense for service rendered by Guizhou Eakan was $2,367,722.
SCHEDULE OF RELATED PARTY TRANSACTIONS	'
	The related party balances at September 30, 2013 and December 31, 2012 are presented as follows:
	Liabilities		Purpose		September 30, 2013	December 31, 2012
					USD	USD
	Other payable – a related party(1)		Commission		316,627	339,272
	Other payable – a related party(2)		Loan		2,373,280	2,311,044
	Other payable – a related party(3)		Contribution		1,518,675	1,431,308
	Total other payable – related parties				4,208,582	4,081,624
	(1)During the year ended December 31, 2011, Guizhou Taibang signed an agency contract with Guizhou Eakan Co., Ltd. (“Guizhou Eakan”), an affiliate of one of the Guizhou Taibang’s noncontrolling interest shareholders, pursuant to which Guizhou Taibang would pay commission to Guizhou Eakan for the promotion of the product of Placenta Polypeptide. At September 30, 2013, Guizhou Taibang accrued commission payable of $316,627 for service rendered by Guizhou Eakan. For the three months ended September 30, 2013, commission expense for service rendered by Guizhou Eakan was $815,410. For the nine months ended September 30, 2013, commission expense for service rendered by Guizhou Eakan was $2,367,722.
	(2)Guizhou Taibang has payables to Guizhou Eakan Investing Corp., amounting to approximately $2,373,280 and $2,311,044 at September 30, 2013 and December 31, 2012, respectively. Guizhou Eakan Investing Corp. is one of the noncontrolling interest shareholders of Guizhou Taibang. The Company borrowed this interest free advance for working capital purpose for Guizhou Taibang. The balance is due on demand.
	(3)Guizhou Taibang has payables to Jie’an, a noncontrolling interest shareholder of Guizhou Taibang, amounting to approximately $1,518,675 and $1,431,308 at September 30, 2013 and December 31, 2012, respectively. In 2007, Guizhou Taibang received additional contributions from Jie’an of $962,853 (or RMB6,480,000) to maintain Jie’an’s equity interest in Guizhou Taibang at 9%. However, due to a legal dispute among shareholders over raising additional capital as discussed in the legal proceeding section (see Note 13), the contribution is subject to be returned to Jie’an. During the second quarter of 2010, Jie’an requested that Guizhou Taibang register its 1.8 million shares of additional capital contribution with the local AIC, pursuant to the Equity Purchase Agreement, and such registration was approved by the majority shareholders of Guizhou Taibang in a shareholders’ meeting held in the second quarter of 2010. However, the Board of Directors of the Company is withholding its required ratification of the shareholders’ approval of Jie’an’s request until the completion of the ongoing litigations. If the Company decided to ratify the approval, Dalin’s ownership in Guizhou Taibang will be diluted from 54% to 52.54% and Jie’an will be entitled to receive its pro rata share of Guizhou Taibang’s profits since the date of Jie’an contribution became effective. As this case is closely tied to the outcome of the strategic investors’ dispute stated above, the Company has set aside Jie’an’s additional fund of RMB5,040,000 (approximately $821,520), the over-paid subscription of RMB1,440,000 (approximately $234,720) along with RMB2,837,024 (approximately $462,435) in accrued interest and penalty at September 30, 2013.

NET_INCOME_PER_SHARE_Tables

NET INCOME PER SHARE (Tables)	9 Months Ended
	Sep. 30, 2013
Net Income Loss Per Share Disclosure [Abstract]	'
SCHEDULE OF EPS- BASIC AND DILUTED	'
	The following table sets forth the computation of basic and diluted net income per share for the periods indicated:
		For the three months ended
		September 30, 2013	September 30, 2012
		USD	USD
	Net income attributable to China Biologic Products, Inc.	14,696,023	13,617,150
	Earnings allocated to participating nonvested shares	-143,220	-20,709
	Net income used in basic/diluted net income per common stock	14,552,803	13,596,441
	Weighted average shares used in computing basic net income per common	26,288,154	26,546,929
	stock
	Diluted effect of stock option	1,160,927	471,975
	Weighted average shares used in computing diluted net income per common	27,449,081	27,018,904
	stock
	Net income per common stock – basic	0.55	0.51
	Net income per common stock – diluted	0.53	0.5
		For the nine months ended
		September 30, 2013	September 30, 2012
		USD	USD
	Net income attributable to China Biologic Products, Inc.	45,773,809	39,413,227
	Earnings allocated to participating nonvested shares	-303,490	-20,562
	Net income allocated to common stockholders used in computing basic net	45,470,319	39,392,665
	income per common stock
	Change in fair value of warrants	-	-1,769,140
	Net income used in diluted net income per common stock	45,470,319	37,623,525
	Weighted average shares used in computing basic net income per common	26,649,563	26,009,707
	stock
	Diluted effect of warrants	-	266,999
	Diluted effect of stock option	1,130,442	465,007
	Weighted average shares used in computing diluted net income per common	27,780,005	26,741,713
	stock
	Net income per common stock – basic	1.71	1.51
	Net income per common stock – diluted	1.64	1.41

BASIS_OF_PRESENTATION_SIGNIFIC2

BASIS OF PRESENTATION, SIGNIFICANT CONCENTRATION AND RISKS (Narrative) (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Total cash at banks and deposits including insured amount	$162,673,942	'	$162,673,942	'	$132,201,606
Cash, Insured Amount	$523,559	'	$523,559	'	$76,101
Customers that individually comprised 10% or more of the total sales	0	0	0	0	'
Suppliers that comprised 10% or more of the total purchases	0	0	0	0	'
Customers represented 10% or more of trade receivables	0	'	0	'	0
Suppliers that represented more than 10% of accounts payables	1	'	1	'	2
Human Albumin [Member]	'	'	'	'	'
Major product sales percentage	49.70%	43.30%	43.30%	45.30%	'
Human Immunoglobulin For Intravenous Injection [Member]	'	'	'	'	'
Major product sales percentage	32.30%	44.10%	39.80%	39.70%	'

ACCOUNTS_RECEIVABLE_Narrative_

ACCOUNTS RECEIVABLE (Narrative) (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Provision for Doubtful Accounts	$0	$0	$0	$21,876

SCHEDULE_OF_ACCOUNTS_RECEIVABL

SCHEDULE OF ACCOUNTS RECEIVABLE (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Accounts receivable	$22,831,402	$11,621,851
Less: Allowance for doubtful accounts	-426,868	-415,607
Total	$22,404,534	$11,206,244

INVENTORIES_Narrative_Details

INVENTORIES (Narrative) (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Write-down of obsolete inventories	$0	$0	$0	$0

SCHEDULE_OF_INVENTORIES_Detail

SCHEDULE OF INVENTORIES (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Raw materials	$40,304,623	$29,596,746
Work-in-process	20,417,588	24,524,142
Finished goods	22,954,562	21,558,285
Total	$83,676,773	$75,679,173

PROPERTY_PLANT_AND_EQUIPMENT_N

PROPERTY, PLANT AND EQUIPMENT (Narrative) (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Depreciation	$1,444,859	$2,045,202	$4,550,598	$4,326,425

SCHEDULE_OF_PROPERTY_PLANT_AND

SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Total property, plant and equipment, gross	$67,528,148	$61,322,144
Accumulated depreciation	-25,032,035	-24,356,752
Total property, plant and equipment, net	42,496,113	36,965,392
Construction in progress	21,021,486	3,501,404
Prepayments for property, plant and equipment	3,608,464	10,858,381
Property, plant and equipment, net	67,126,063	51,325,177
Buildings [Member]	'	'
Total property, plant and equipment, gross	31,252,689	25,183,496
Machinery and Equipment [Member]	'	'
Total property, plant and equipment, gross	29,064,844	29,625,166
Furniture, Fixtures, Office Equipment and Vehicles [Member]	'	'
Total property, plant and equipment, gross	$7,210,615	$6,513,482

INTANGIBLE_ASSETS_NET_Narrativ

INTANGIBLE ASSETS, NET (Narrative) (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Amortization expense for amortizing intangible assets	$257,318	$730,994	$912,470	$2,187,804
2014	513,226	'	513,226	'
2015	511,439	'	511,439	'
2016	505,852	'	505,852	'
2017	471,598	'	471,598	'
2018	$428,585	'	$428,585	'

SCHEDULE_OF_INTANGIBLE_ASSETS_

SCHEDULE OF INTANGIBLE ASSETS (Details) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Gross carrying amount	$15,784,183	$15,247,052
Accumulated Amortization	-12,943,633	-11,705,470
Net carrying amount	2,840,550	3,541,582
Permits and Licenses [Member]	'	'
Weighted average amortization period	'10 years	'10 years
Gross carrying amount	5,122,788	4,987,647
Accumulated Amortization	-2,614,623	-2,119,622
Net carrying amount	2,508,165	2,868,025
GMP Certificate [Member]	'	'
Weighted average amortization period	'5 years	'5 years
Gross carrying amount	2,594,112	2,525,679
Accumulated Amortization	-2,445,289	-1,955,360
Net carrying amount	148,823	570,319
Long-Term Customer-Relationship [Member]	'	'
Weighted average amortization period	'4 years	'4 years
Gross carrying amount	7,722,940	7,519,206
Accumulated Amortization	-7,722,940	-7,519,206
Net carrying amount	0	0
Others [Member]	'	'
Gross carrying amount	344,343	214,520
Accumulated Amortization	-160,781	-111,282
Net carrying amount	$183,562	$103,238

DEPOSITS_RELATED_TO_LAND_USE_R1

DEPOSITS RELATED TO LAND USE RIGHTS (Narrative) (Details)	Sep. 30, 2013	Sep. 30, 2013
	USD ($)	CNY
Deposits related to land use rights	$13,594,200	83,400,000

RESTRICTED_CASH_AND_DEPOSIT_Na

RESTRICTED CASH AND DEPOSIT (Narrative) (Details)	9 Months Ended			0 Months Ended
	Sep. 30, 2013	Sep. 30, 2013	Dec. 31, 2012	Nov. 01, 2012	Nov. 01, 2012	Sep. 30, 2013	Sep. 30, 2013	Aug. 07, 2013
	USD ($)	CNY	USD ($)	Technical upgrade subsidy [Member]	Technical upgrade subsidy [Member]	China Merchants Bank Beijing Branch [Member]	China Merchants Bank Beijing Branch [Member]	China Merchants Bank Beijing Branch [Member]
				USD ($)	CNY	USD ($)	CNY	USD ($)
Restricted cash and deposit	$32,064,962	'	$2,912,145	$2,991,050	18,350,000	'	'	'
Restricted cash and cash equivalent item agreement validity	'	'	'	'3 years	'3 years	'	'	'
Restricted cash used in the technical upgrade in respect of the new GMP standard	1,244,088	7,632,444	'	'	'	'	'	'
Time deposits	'	'	'	'	'	30,318,000	186,000,000	'
Restricted Cash and Cash Equivalents	1,746,962	10,717,556	'	'	'	'	'	'
Deposit liabilities, collateral issued, financial instruments	'	'	'	'	'	'	'	$30,000,000

BANK_LOANS_Narrative_Details

BANK LOANS (Narrative) (Details)	3 Months Ended		9 Months Ended		0 Months Ended	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Aug. 08, 2013	Sep. 30, 2013	Sep. 30, 2013
	USD ($)	USD ($)	USD ($)	USD ($)	China Merchants Bank Beijing Branch [Member]	China Merchants Bank Beijing Branch [Member]	China Merchants Bank Beijing Branch [Member]
					USD ($)	USD ($)	CNY
Interest expense on short-term bank loans	$79,195	$91,919	$273,095	$296,901	'	'	'
Interest-bearing deposit liabilities, Total	'	'	'	'	30,000,000	'	'
Loan lent period	'	'	'	'	'	'18 months	'18 months
Debt instrument, interest rate terms	'	'	'	'	'3-month	'	'
Line of credit facility, interest rate description	'	'	'	'	'3-month LIBOR plus 1.6%	'	'
Line of credit facility, commitment fee percentage	'	'	'	'	0.70%	'	'
Time deposits	'	'	'	'	'	$30,318,000	186,000,000

SCHEDULE_OF_SHORTTERM_BANK_LOA

SCHEDULE OF SHORT-TERM BANK LOANS (Details) (USD $)	9 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Short-term Debt	$4,890,000	$7,935,000
Unsecured Loan 1 [Member]	'	'
Maturity date	1-Aug-13	'
Annual interest rate	6.00%	'
Unsecured Debt, Current	0	3,174,000
Unsecured Loan 2 [Member]	'	'
Maturity date	3-Sep-13	'
Annual interest rate	6.00%	'
Unsecured Debt, Current	0	3,174,000
Unsecured Loan 3 [Member]	'	'
Maturity date	3-Sep-13	'
Annual interest rate	6.00%	'
Unsecured Debt, Current	0	1,587,000
Unsecured Loan 4 [Member]	'	'
Maturity date	12-May-14	'
Annual interest rate	6.00%	'
Unsecured Debt, Current	$4,890,000	$0

INCOME_TAX_Narrative_Details

INCOME TAX (Narrative) (Details)	0 Months Ended	1 Months Ended	3 Months Ended		9 Months Ended
	Jul. 27, 2011	Oct. 31, 2011	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Companys effective income tax rates	'	'	20.00%	16.00%	17.00%	15.00%
Preferential tax rate	15.00%	15.00%	'	'	'	'

OPTIONS_AND_NONVESTED_SHARES_N

OPTIONS AND NONVESTED SHARES (Narrative) (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Number of Options, Granted	'	'	33,000	'
Stock compensation expense related to options	$651,047	$1,028,860	$3,346,046	$3,021,818
Weighted average grant date fair value of options granted	'	'	$8.37	'
Aggregate fair value of options granted	'	'	276,250	'
Stock compensation expense with respect to non-vested stock option	4,082,914	'	4,082,914	'
Stock compensation expense to be recognized with respect to non-vested stock option	'	'	'2 years 5 months 26 days	'
Stock compensation expense related to nonvested shares	377,808	52,314	730,771	52,314
Stock compensation expense to be recognized with respect to non-vested shares	$6,983,867	'	$6,983,867	'
Stock compensation expense with respect to non-vested shares weighted average vesting period	'	'	'3 years 5 months 5 days	'

SCHEDULE_OF_STOCK_OPTIONS_ACTI

SCHEDULE OF STOCK OPTIONS ACTIVITY (Details) (USD $)	9 Months Ended
	Sep. 30, 2013
Outstanding, Number of Options	2,648,609
Outstanding, Weighted Average Exercise Price	$9.39
Outstanding, Weighted Average Remaining Contractual Term in Years	'7 years 7 months 24 days
Outstanding, Aggregate Intrinsic Value	$18,374,422
Number of Options, Granted	33,000
Weighted Average Exercise Price, Granted	$10.48
Number of Options, Exercised	-353,191
Weighted Average Exercise Price, Exercised	$8.59
Aggregate Intrinsic Value, Exercised	4,669,588
Number of Options, Forfeited and expired	-150,680
Weighted Average Exercise Price, Forfeited and expired	$6.78
Outstanding, Number of Options	2,177,738
Outstanding, Weighted Average Exercise Price	$9.71
Outstanding, Weighted Average Remaining Contractual Term in Years	'7 years 2 months 12 days
Outstanding, Aggregate Intrinsic Value	42,462,885
Number of Options, Vested and expected to vest	2,177,738
Weighted Average Exercise Price, Vested and expected to vest	$9.71
Weighted Average Remaining Contractual Term in Years, Vested and expected to vest	'7 years 2 months 12 days
Vested and expected to vest, Aggregate Intrinsic Value	42,462,885
Number of Options, Exercisable	1,617,738
Weighted Average Exercise Price, Exercisable	$9.73
Weighted Average Remaining Contractual Term in Years, Exercisable	'6 years 7 months 28 days
Aggregate Intrinsic Value, Exercisable	$31,509,285

SCHEDULE_OF_STOCK_OPTIONS_VALU

SCHEDULE OF STOCK OPTIONS VALUATION ASSUMPTION (Details) (USD $)	9 Months Ended
	Sep. 30, 2013
Expected volatility	104.00%
Expected dividends yield	0.00%
Expected term	'5 years
Risk-free interest rate (per annum)	0.72%
Fair value of underlying ordinary shares (per share)	$10.57

SCHEDULE_OF_NONVESTED_SHARES_A

SCHEDULE OF NONVESTED SHARES ACTIVITY (Details) (Non Vested Shares [Member], USD $)	9 Months Ended
	Sep. 30, 2013
Non Vested Shares [Member]	'
Number of nonvested shares, Outstanding	120,000
Grant date weighted average fair value, Outstanding	$9.85
Number of nonvested shares, Granted	296,500
Grant date weighted average fair value, Granted	$22.74
Number of nonvested shares, Vested	-63,750
Grant date weighted average fair value, Vested	$9.85
Number of nonvested shares, Forfeited	0
Grant date weighted average fair value, Forfeited	$0
Number of nonvested shares, Outstanding	352,750
Grant date weighted average fair value, Outstanding	$20.68

SCHEDULE_OF_SALES_BY_PRODUCT_T

SCHEDULE OF SALES BY PRODUCT TYPE (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Sales	$53,152,141	$53,124,050	$160,764,396	$150,817,850
Human Albumin [Member]	'	'	'	'
Sales	26,420,902	22,990,891	69,686,924	68,320,593
Human Immunoglobulin For Intravenous Injection [Member]	'	'	'	'
Sales	17,162,545	23,412,548	63,921,570	59,913,448
Other Immunoglobulin Products [Member]	'	'	'	'
Sales	5,355,020	3,685,613	15,949,006	14,458,714
Placenta Polypeptide [Member]	'	'	'	'
Sales	2,762,092	2,726,801	7,984,246	7,346,812
Others [Member]	'	'	'	'
Sales	$1,451,582	$308,197	$3,222,650	$778,283

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Narrative) (Details)

Sep. 30, 2013

Sep. 30, 2013

Apr. 30, 2013

Apr. 30, 2013

31-May-09

Jun. 30, 2007

31-May-12

Jan. 31, 2012

Jan. 31, 2012

Nov. 30, 2010

Nov. 30, 2010

Jun. 30, 2010

Dec. 31, 2011

Dec. 31, 2011

Sep. 30, 2013

Sep. 30, 2013

31-May-07

31-May-07

USD ($)

CNY

USD ($)

CNY

Equity Purchase Agreements [Member]

Equity Purchase Agreements [Member]

Dispute Among Guizhou Taibang Shareholders Over Raising Additional Capital [Member]

Dispute Among Guizhou Taibang Shareholders Over Raising Additional Capital [Member]

Dispute Among Guizhou Taibang Shareholders Over Raising Additional Capital [Member]

Dispute Among Guizhou Taibang Shareholders Over Raising Additional Capital [Member]

Dispute Among Guizhou Taibang Shareholders Over Raising Additional Capital [Member]

Dispute Among Guizhou Taibang Shareholders Over Raising Additional Capital [Member]

Dispute Among Guizhou Taibang Shareholders Over Raising Additional Capital [Member]

Dispute Among Guizhou Taibang Shareholders Over Raising Additional Capital [Member]

Dispute Among Guizhou Taibang Shareholders Over Raising Additional Capital [Member]

Dispute Among Guizhou Taibang Shareholders Over Raising Additional Capital [Member]

Dispute Among Guizhou Taibang Shareholders Over Raising Additional Capital [Member]

Dispute Among Guizhou Taibang Shareholders Over Raising Additional Capital [Member]

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

91% controlling interest of Guizhou Taibang's shareholders

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

91.00%

91.00%

Issuance of an additional 20,000,000 shares of Guizhou Taibang

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20,000,000

20,000,000

Shares price of additionally issued shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2.8

Remaining 9% noncontrolling interest

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9.00%

9.00%

Investors agreed to invest

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$7,475,832

50,960,000

Exchange for 18,200,000 shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

18,200,000

18,200,000

21.4%, of Guizhou Taibang's equity interests

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

21.40%

21.40%

Subscribed for 1,800,000 shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,800,000

1,800,000

Share of the 20,000,000 shares being offered

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20,000,000

20,000,000

Right to acquire common stock shares

'

'

'

'

'

18,200,000

'

'

'

'

'

'

'

'

'

'

'

'

Company returned proceeds

'

'

'

'

'

'

'

'

'

1,699,040

11,200,000

'

'

'

'

'

'

'

Request for distribution of dividends of $2,990,943 (or RMB 18,349,345)

'

'

'

'

'

'

'

2,990,943

18,349,345

'

'

'

'

'

'

'

'

'

Request for interest in amount of $464,061 (or RMB 2,847,000)

'

'

'

'

'

'

'

464,061

2,847,000

'

'

'

'

'

'

'

'

'

Requested that Guizhou Taibang register its 1.8 million shares of additional capital infusion with the local AIC

'

'

'

'

'

'

'

'

'

'

'

1,800,000

'

'

'

'

'

'

Related interest and penalty from May 2007 to December 2011 amounting to RMB 25,000,000

'

'

'

'

'

'

'

'

'

'

'

'

3,967,500

25,000,000

'

'

'

'

Return over - paid subscription

'

'

'

'

'

'

'

'

'

'

'

'

228,528

1,440,000

'

'

'

'

Interest and penalty, amounting to RMB 10,000,000 (approximately $1,587,000) in aggregate

'

'

'

'

'

'

'

'

'

'

'

'

1,587,000

10,000,000

'

'

'

'

Dalins ownership in Guizhou Taibang will be diluted from 54%

'

'

'

'

'

'

54.00%

'

'

'

'

'

'

'

'

'

'

'

Diluted to 52.54%

'

'

'

'

'

'

52.54%

'

'

'

'

'

'

'

'

'

'

'

Payables to Jie'an for the additional funds received

'

'

'

'

'

'

'

'

'

'

'

'

'

'

821,520

5,040,000

'

'

Payables to Jie'an for over-paid subscription

234,720

1,440,000

'

'

'

'

'

'

'

'

'

'

'

'

234,720

1,440,000

'

'

Payable to Jie'an for the accrued interest

'

'

'

'

'

'

'

'

'

'

'

'

'

'

462,435

2,837,024

'

'

Gain Contingency, Unrecorded Amount

'

'

6,064,800

38,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Capital commitment,amount commited

$4,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Denied the rights of first refusal of Jieban over the 18,200,000 shares

'

'

'

'

18,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

RELATED_PARTY_TRANSACTIONS_Nar

RELATED PARTY TRANSACTIONS (Narrative) (Details)	3 Months Ended		9 Months Ended	12 Months Ended
Share data in Millions, unless otherwise specified	Sep. 30, 2013	Jun. 30, 2010	Sep. 30, 2013	Dec. 31, 2007	Dec. 31, 2007	Sep. 30, 2013	Dec. 31, 2012
	USD ($)		USD ($)	USD ($)	CNY	CNY	USD ($)
Accrued Sales Commission	$316,627	'	$316,627	'	'	'	$339,272
Commission expense for service rendered	815,410	'	2,367,722	'	'	'	'
Payables to Guizhou Eakan Investing Corp.	2,373,280	'	2,373,280	'	'	'	2,311,044
Guizhou Taibang received additional contributions from Jie'an of $962,853 to maintain Jie'an equity interest	'	'	'	962,853	6,480,000	'	'
Jieban requested that Guizhou Taibang register its 1.8 million shares of additional capital contribution with the local AIC	'	1.8	'	'	'	'	'
Dalins ownership in Guizhou Taibang will be diluted from 54%	'	'	54.00%	'	'	'	'
Ownership in Guizhou Taibang will be diluted to 52.54%	'	'	52.54%	'	'	'	'
Jie'an's additional fund	821,520	'	821,520	'	'	5,040,000	'
Accrued interest and penalty for Jie'an's additional fund	462,435	'	462,435	'	'	2,837,024	'
Payables to Jie'an Noncontrolling Interest	1,518,675	'	1,518,675	'	'	'	1,431,308
Maintain Jie'an equity interest in Guizhou Taibang at 9%	'	'	'	9.00%	9.00%	'	'
Payables to Jie'an for over-paid subscription	$234,720	'	$234,720	'	'	1,440,000	'

SCHEDULE_OF_MATERIAL_RELATED_P

SCHEDULE OF MATERIAL RELATED PARTY TRANSACTIONS (Details) (USD $)	3 Months Ended				9 Months Ended
	Sep. 30, 2013		Sep. 30, 2012		Sep. 30, 2013		Sep. 30, 2012
Related Party Transactions [Line Items]	'		'		'		'
Commission expenses with related parties	$815,410	[1]	$1,014,193	[1]	$2,367,722	[1]	$2,594,281	[1]
[1]	During the year ended December 31, 2011, Guizhou Taibang signed an agency contract with Guizhou Eakan Co., Ltd. (bGuizhou Eakanb), an affiliate of one of the Guizhou Taibangbs noncontrolling interest shareholders, pursuant to which Guizhou Taibang would pay commission to Guizhou Eakan for the promotion of the product of Placenta Polypeptide. At September 30, 2013, Guizhou Taibang accrued commission payable of $316,627 for service rendered by Guizhou Eakan. For the three months ended September 30, 2013, commission expense for service rendered by Guizhou Eakan was $815,410. For the nine months ended September 30, 2013, commission expense for service rendered by Guizhou Eakan was $2,367,722.

SCHEDULE_OF_RELATED_PARTY_TRAN

SCHEDULE OF RELATED PARTY TRANSACTIONS (Details) (USD $)	Sep. 30, 2013		Dec. 31, 2012
Due to Related Parties, Current	$4,208,582		$4,081,624
Commission [Member]	'		'
Due to Related Parties, Current	316,627	[1]	339,272	[1]
Loan [Member]	'		'
Due to Related Parties, Current	2,373,280	[2]	2,311,044	[2]
Contribution [Member]	'		'
Due to Related Parties, Current	$1,518,675	[3]	$1,431,308	[3]
[1]	During the year ended December 31, 2011, Guizhou Taibang signed an agency contract with Guizhou Eakan Co., Ltd. (bGuizhou Eakanb), an affiliate of one of the Guizhou Taibangbs noncontrolling interest shareholders, pursuant to which Guizhou Taibang would pay commission to Guizhou Eakan for the promotion of the product of Placenta Polypeptide. At September 30, 2013, Guizhou Taibang accrued commission payable of $316,627 for service rendered by Guizhou Eakan. For the three months ended September 30, 2013, commission expense for service rendered by Guizhou Eakan was $815,410. For the nine months ended September 30, 2013, commission expense for service rendered by Guizhou Eakan was $2,367,722.
[2]	Guizhou Taibang has payables to Guizhou Eakan Investing Corp., amounting to approximately $2,373,280 and $2,311,044 at September 30, 2013 and December 31, 2012, respectively. Guizhou Eakan Investing Corp. is one of the noncontrolling interest shareholders of Guizhou Taibang. The Company borrowed this interest free advance for working capital purpose for Guizhou Taibang. The balance is due on demand.
[3]	Guizhou Taibang has payables to Jieban, a noncontrolling interest shareholder of Guizhou Taibang, amounting to approximately $1,518,675 and $1,431,308 at September 30, 2013 and December 31, 2012, respectively. In 2007, Guizhou Taibang received additional contributions from Jieban of $962,853 (or RMB6,480,000) to maintain Jiebanbs equity interest in Guizhou Taibang at 9%. However, due to a legal dispute among shareholders over raising additional capital as discussed in the legal proceeding section (see Note 13), the contribution is subject to be returned to Jieban. During the second quarter of 2010, Jieban requested that Guizhou Taibang register its 1.8 million shares of additional capital contribution with the local AIC, pursuant to the Equity Purchase Agreement, and such registration was approved by the majority shareholders of Guizhou Taibang in a shareholdersb meeting held in the second quarter of 2010. However, the Board of Directors of the Company is withholding its required ratification of the shareholdersb approval of Jiebanbs request until the completion of the ongoing litigations. If the Company decided to ratify the approval, Dalinbs ownership in Guizhou Taibang will be diluted from 54% to 52.54% and Jieban will be entitled to receive its pro rata share of Guizhou Taibangbs profits since the date of Jieban contribution became effective. As this case is closely tied to the outcome of the strategic investorsb dispute stated above, the Company has set aside Jiebanbs additional fund of RMB5,040,000 (approximately $821,520), the over-paid subscription of RMB1,440,000 (approximately $234,720) along with RMB2,837,024 (approximately $462,435) in accrued interest and penalty at September 30, 2013.

NET_INCOME_PER_SHARE_Narrative

NET INCOME PER SHARE (Narrative) (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Options excluded from the calculation of diluted net income per share of common stock	0	1,979,333	0	1,979,333
Average exercise price of options excluded from the calculation of diluted net income per share of common stock	'	$11.37	'	$11.37

SCHEDULE_OF_NET_INCOME_PER_SHA

SCHEDULE OF NET INCOME PER SHARE RECONCILIATION (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Net income attributable to China Biologic Products, Inc.	$14,696,023	$13,617,150	$45,773,809	$39,413,227
Earnings allocated to participating nonvested shares	-143,220	-20,709	-303,490	-20,562
Net income used in basic/diluted net income per common stock	14,552,803	13,596,441	'	'
Net income allocated to common stockholders used in computing basic net income per common stock	'	'	45,470,319	39,392,665
Change in fair value of warrants	'	'	0	-1,769,140
Net income used in diluted net income per common stock	'	'	$45,470,319	$37,623,525

SCHEDULE_OF_NET_INCOME_PER_SHA1

SCHEDULE OF NET INCOME PER SHARE - BASIC AND DILUTED (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Weighted average shares used in computing basic net income per common stock	26,288,154	26,546,929	26,649,563	26,009,707
Diluted effect of warrants	'	'	0	266,999
Diluted effect of stock option	1,160,927	471,975	1,130,442	465,007
Weighted average shares used in computing diluted net income per common stock	27,449,081	27,018,904	27,780,005	26,741,713
Net income per common stock - basic	$0.55	$0.51	$1.71	$1.51
Net income per common stock - diluted	$0.53	$0.50	$1.64	$1.41

SHARE_REPURCHASE_Narrative_Det

SHARE REPURCHASE (Narrative) (Details) (USD $)	0 Months Ended
	Aug. 08, 2013
Treasury Stock, Shares, Acquired	1,479,704
Treasury Stock Value Acquired	$29,594,080